Navigation Links
Spectral announces first quarter 2009 results
Date:5/14/2009

TORONTO, May 14 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc., (TSX: SDI), a company focused on bringing to market a diagnostic and a therapeutic targeting severe sepsis, today announced its financial results for the first quarter ended March 31, 2009.

"This quarter, we achieved an important milestone by securing the exclusive rights to develop and commercialize Toraymyxin(TM) for the US market after thorough due diligence into the product and its potential market opportunity," said Dr. Paul Walker, President and CEO of Spectral. "Toraymyxin(TM) has been used on more than 70,000 patients to date, primarily in Europe and Japan, for the treatment of severe sepsis and has demonstrated a significant reduction in the mortality of patients with severe sepsis compared to standard of care. We believe that, when used together with our proprietary Endotoxin Activity Assay (EAA(TM)), Toraymyxin(TM) represents a significant medical advance in helping doctors manage a devastating disease. Our next steps will be to obtain an Investigational Device Exemption (IDE) from the US FDA and to initiate a registration trial for Toraymyxin(TM) in 2009."

    First quarter 2009 highlights:

    -   Data on the clinical utility of EAA(TM) and Toraymyxin(TM) was
        featured in a key scientific symposium entitled, "The Role of
        Endotoxin," that included presentations from six thought leaders in
        the field of sepsis, at the 29th International Symposium on Intensive
        Care and Emergency Medicine in Brussels, Belgium in March.

    -   New findings demonstrating the clinical utility of EAA(TM) were
        presented at the 13th Annual Critical Care for Endotoxemia Congress.
        The conference took place in Tokyo, Japan in February.

    -   A final license and supply agreement was signed with Toray
        Industries, Inc. for the exclusive development and commercial rights
        in the U.S. for Toraymyxin(TM) in
'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Spectral announces 2007 financial results
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Results from a Phase III ... its ability to reduce the size of melanoma tumors ... in the Journal of Clinical Oncology. , The ... IIIC and IV melanoma, a potentially fatal form of ... to evaluate the safety and efficacy of the oncolytic ...
(Date:5/28/2015)... May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ... Markets, and Companies" to their offering. ... This report deals with therapeutic drug ... improving patient care by monitoring drug levels ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has announced ... Products, by Testing services - Global Forecast to 2020" ... animal genetics market is estimated to be worth around ... of 8-9% during the forecast period of 2014 to ... increasing animal protein consumption, increasing adoption of advanced genetic ...
(Date:5/28/2015)... N.J. , May 28, 2015 Celsion ... that it has received commitments from two institutional healthcare ... of the Company,s common stock in an at-the-market registered ... to purchase common stock. The Company entered ... to which the Company agreed to sell an aggregate ...
Breaking Biology Technology:Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Therapeutic Drug Monitoring Market 2015-2024 2Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3
... NORTH VANCOUVER, April 16 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ... on its on-going restructuring efforts., The Board of ... stepped down as President and Chief Executive Officer, effective,immediately. ... Mr. Duncan, a,founder of the Company, served as President ...
... Annual Meeting of the American ... Association for Cancer Research (AACR) -, ... LOR; AMEX: LRP), a biopharmaceutical company specializing,in the research, ... management of cancer, today announced,presentations of further preclinical data ...
... the National Institute of Standards and Technology (NIST) ... on a single microchip, a cryogenic sensor and ... cheaper, simpler and faster precision analysis of materials ... in an upcoming issue of Applied Physics Letters,* ...
Cached Biology Technology:Chromos provides shareholder update 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 3Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 4NIST micro sensor and micro fridge make cool pair 2
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/6/2015)... Israel , May 6, 2015 LifeBEAM, ... most established helmet producer, announced today that they will ... Helmet, the world,s first bio-sensing cycling helmet and the ... released in two new colors in order to give ... the product. In addition, LifeBEAM and Lazer announced their ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... that proteins on the surface of a cell twist a ... and cause disease, all in a movement as graceful as ... issue of Nature Structural & Molecular Biology . ... biologist, describes the crucial initial steps taken by attachment proteins ...
... a compound in grapes, displays antioxidant and other positive ... the UT Health Science Center San Antonio describe a ... effects. Resveratrol stimulates the expression of adiponectin, a ... the team found. Adiponectin has a wide range of ...
... in the United States do not grasp the scientific ... in understanding the causes and consequences of climate change, ... BioScience . The study, whose authors include ... calls for a new way of teaching and, ...
Cached Biology News:Mayo researchers describe measles viral protein movement 2Grape ingredient resveratrol increases beneficial fat hormone 2College students lack scientific literacy, study finds 2